What is SELLAS Life Sciences Group?
SELLAS Life Sciences Group is a late-stage biopharmaceutical firm dedicated to advancing the development of innovative cancer immunotherapies and therapeutics for a wide array of cancer indications. Its primary product candidate, galinpepimut-S, is a cancer immunotherapeutic agent acquired from Memorial Sloan Kettering Cancer Center. This agent is designed to target a broad spectrum of hematologic cancers and solid tumor indications. Headquartered in New York, NY, SELLAS is strategically positioned to leverage its pipeline for significant market impact.
How much funding has SELLAS Life Sciences Group raised?
SELLAS Life Sciences Group has raised a total of $20M across 1 funding round:
Share Placement
$20M
Share Placement (2023): $20M, investors not publicly disclosed
What's next for SELLAS Life Sciences Group?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for SELLAS Life Sciences Group. This capital infusion is expected to accelerate the clinical development and potential commercialization of galinpepimut-S, as well as support the expansion of its research and development pipeline. The company's focus on novel immunotherapies places it at the forefront of oncology innovation, with future developments likely centered on advancing its lead candidate through late-stage trials and exploring new therapeutic avenues.
See full SELLAS Life Sciences Group company page
